Key facts
- This page summarizes Phillip A. Sharp's Form 4 filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY).
- 8 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Mar 2024, 16:12.
Phillip A. Sharp - 29 Feb 2024 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)
- Reporting relationship
- Director
- Issuer ticker
- ALNY
- Reported as of
- 29 Feb 2024
- Net transaction value
- -$2,762,571
- SEC form
- 4
- Accepted by SEC
- 01 Mar 2024, 16:12:55 UTC
- Prior SEC filing
- 24 May 2023
- Next SEC filing
- 20 May 2024
- Source filing
- View source filing
- Reporting owner signature
- By: Stephen Hall, Attorney-in-Fact For: Phillip A. Sharp
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Phillip A. Sharp filed Form 4 for ALNYLAM PHARMACEUTICALS, INC. (ALNY) on 01 Mar 2024.
Change
- Previous filing in this sequence was filed on 24 May 2023.
- Current net transaction value: -$2,762,571.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALNY
transaction
Common Stock
Options Exercise
- Transaction value
- $1,777,500
- Shares
- +30,000
- Change %
- Price
- $59.25
- Shares after
- 30,000
- Date
- 29 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
ALNY
transaction
Common Stock
Sale
- Transaction value
- $1,958,553
- Shares
- -13,005
- Change %
- -43%
- Price
- $150.60
- Shares after
- 16,995
- Date
- 29 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
ALNY
transaction
Common Stock
Sale
- Transaction value
- $2,052,937
- Shares
- -13,557
- Change %
- -80%
- Price
- $151.43
- Shares after
- 3,438
- Date
- 29 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F3
ALNY
transaction
Common Stock
Sale
- Transaction value
- $139,446
- Shares
- -915
- Change %
- -27%
- Price
- $152.40
- Shares after
- 2,523
- Date
- 29 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F4
ALNY
transaction
Common Stock
Sale
- Transaction value
- $292,800
- Shares
- -1,906
- Change %
- -76%
- Price
- $153.62
- Shares after
- 617
- Date
- 29 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F5
ALNY
transaction
Common Stock
Sale
- Transaction value
- $15,561
- Shares
- -101
- Change %
- -16%
- Price
- $154.07
- Shares after
- 516
- Date
- 29 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F6
ALNY
transaction
Common Stock
Sale
- Transaction value
- $80,775
- Shares
- -516
- Change %
- -100%
- Price
- $156.54
- Shares after
- 0
- Date
- 29 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F7
ALNY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 266,899
- Date
- 29 Feb 2024
- Ownership
- by Trust
- Footnotes
- F8
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALNY
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -30,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 29 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $59.25
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 8 footnotes
Footnote F1
The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2023. The 30,000 options exercised and sold by the reporting person were due to expire on June 4, 2024.
Footnote F2
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $150.00 to $151.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F3
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $151.01 to $151.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F4
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $152.02 to $152.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F5
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.04 to $154.03. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F6
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.06 to $154.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F7
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $156.15 to $156.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Footnote F8
Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.